As a Crohn's patient who's struggled with the stricturing phenotype for 35 years, I'm most excited about TL1A, as that mechanism could mean the end of surgeries for me. Then, the fact that there are multiple other drugs with other mechanisms coming should TL1A prove liable to wane in efficacy, is encouraging, too.
Great summary. I have been looking into these insights from past 6 months and was curious to see the advances ongoing in IBD. Very informative.
Great summary , Charlie . Your enthusiasm for finding a a better tomorrow for IBD is inspiring and infectious!
As a Crohn's patient who's struggled with the stricturing phenotype for 35 years, I'm most excited about TL1A, as that mechanism could mean the end of surgeries for me. Then, the fact that there are multiple other drugs with other mechanisms coming should TL1A prove liable to wane in efficacy, is encouraging, too.